The RMS4.99 study was designed to explore the role of early sequential intensified chemotherapy (SICT) with PBSC rescue in patients with soft tissue sarcoma with a poor prognosis. Fourteen patients with desmoplastic small round-cell tumor (DSRCT) were included in this study. Initial chemotherapy was followed by a course of CY and etoposide with subsequent PBSC harvest, then three consecutive intensified chemotherapy combinations followed by PBSC rescue and G-CSF administration: first cycle thiotepa (150 mg/m 2 Â 2 on day 1) and melphalan (60 mg/m 2 on day 2), second cycle CY (2 g/m 2 on days 1 and 2) and thiotepa (150 mg/m 2 Â 2 on day 3), third cycle melphalan (80 mg/m 2 on day 1). The interval between cycles had to be kept as short as possible. Then patients underwent surgery or radiotherapy or both, after which six courses of vincristine, actinomycin D, CY were administered. Ten patients received SICT, which was well tolerated. With a median follow-up of 27 months only three patients are alive without evidence of disease. The 3-year event-free and overall survival rates were 15.5 and 38.9%, respectively. The prognosis for pediatric patients with DSRCT did not improve after administering intensified chemotherapy early in their treatment, so different strategies are needed.
Introduction
Desmoplastic small round-cell tumor (DSRCT) is a rare, aggressive tumor that mainly affects young men. It typically presents as a large abdominal mass with a marked tendency to spread locally to the regional lymph nodes and peritoneum, and to distant organs such as the liver, lungs and bones.
It is distinguishable from other small round-cell tumors by a characteristic histological appearance with a nesting pattern of cellular growth within abundant desmoplastic stroma, and a specific polyphenotypic differentiation with the co-expression of epithelial, mesenchymal and neural markers. A chromosomal translocation, t (11, 22 )(p13;q12), involving the EWS and the WT1 genes is highly specific for this tumor. 1 Despite aggressive multimodal treatment, few long-term survivors are reported in most reports. [2] [3] [4] [5] [6] Initial experiences with high-dose chemotherapy (HDCT) followed by stem cell rescue have been reported with conflicting results. 7, 8 In these studies, chemotherapy was intensified at the end of standard treatment.
In 1999, the STSC (Soft Tissue Sarcoma Committee) affiliated to the AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) opened the RMS4.99 multicenter study. In this protocol we hypothesized that sequentially administering an intensified chemotherapy earlier than in previous experiences might have been able to prevent the onset of drug resistance and improve the survival of patients with metastatic and highly aggressive pediatric sarcoma. Here we describe the results achieved in a group of patients with DSRCT treated prospectively with this sequential intensified chemotherapy (SICT) strategy.
Materials and methods
From January 1999 to August 2008, 14 patients with DSRCT, ranging in age from 2 to 17.8 years (median 10.3 years) were enrolled in the RMS4.99 protocol. Histology was reviewed centrally in all cases by the STSC Pathology panel. The EWS-WT1 fusion transcript was sought whenever biological material was available.
After the diagnostic work-up (including X-ray, CT scan or MRI, and ultrasound, bone scintigraphy, bone marrow aspiration and biopsy), a 9-week induction phase . Details of this combination have been published elsewhere. 9 After the induction phase, tumor response was evaluated on the primary and metastatic lesions. This was followed by a cycle with CY 2 g/m 2 on days 1 and 2, and etoposide 200 mg/m 2 on days 1, 2 and 3 to obtain a minimum of 2 Â 10 6 /kg CD34 PBSCs per transplant. This was followed by three consecutive intensified-dose combinations, with subsequent G-CSF administration and PBSC rescue. The drugs administered included thiotepa (150 mg/m 2 Â 2 on day 1) and melphalan (60 mg/m 2 on day 2) in the first cycle, CY (2 g/m 2 on days 1 and 2) and thiotepa (150 mg/m 2 Â 2 on day 3) in the second cycle and melphalan (80 mg/m 2 on day 1) in the third cycle. During the SICT phase, the planned interval between cycles was 3 weeks. The chemotherapy cycles were to be started only if all the following conditions were met: 0.5 Â 10 9 /liter neutrophils, 50 Â 10 9 /liter platelets and absence of any relevant organ dysfunction. After a 1-week delay, however, a lower but stable neutrophil or platelet count or both were considered acceptable for the following cycle to start, providing the patient was in good condition and appropriate transfusional and supportive care was given.
Surgery was planned after the SICT. This was followed by radiotherapy to the primary and metastatic sites, if possible.
A hyperfractionated accelerated radiotherapy strategy was adopted with two daily fractions of 1.6 Gy up to a total dose of 44.8 Gy. Macroscopic residual disease was 'boosted' up to a total dose of 54.4 Gy. In cases of malignant ascites or peritoneal dissemination, whole abdominal irradiation with 15 Gy was recommended. . Details of this pilot study have already been published. 10 Definition of response and statistics A formal assessment of the primary tumor and all sites of metastases had to be performed after the induction (ninth week) and SICT phases, as well as at the end of the whole treatment. The response criteria used were as follows: complete response (CR) ¼ resolution of all evidence of disease; partial response (PR) ¼ a tumor volume reduction of more than 66%, minor partial response (minor PR) ¼ a tumor volume reduction of less than 66%, but more than 33%; heterogeneous response (HR) ¼ PR at one or more sites but less than PR at other sites, with no progressive disease (PD); a reduction in volume of less than 33% was recorded as stable disease (SD). An increase in tumor size or the detection of new lesions was considered as PD. Responses had to last at least 4 weeks after the assessment of the response.
Survival curves were calculated according to the KaplanMeier method. The overall survival (OS) curve was calculated considering the time interval between the date of diagnosis and the date of latest follow-up or death from any cause. For event-free survival (EFS), the interval between diagnosis and the date of latest follow-up, relapse or death was considered.
The ethics committees at each center taking part in the study approved the study and informed consent was obtained for all patients enrolled in the protocol.
Results
The clinical characteristics of the study population and the treatment given are shown in Table 1 . Nearly all patients were men. The only woman was mentally retarded due to postnatal complications. As expected, there was a predominance of intraabdominal/pelvic tumors, most of them presenting as very large, invasive masses. In most cases, extensive regional spread was shown by the presence of multiple neoplastic lesions (in seven children), serosal implants (seven), regional lymph node invasion (five) and ascites (four). Peritoneal lesions were often discovered at the time of surgery rather than at initial diagnostic imaging investigations.
Metastatic involvement was evident in the liver, spleen, lung and bone, often with multiple lesions in the same organ. Bone marrow aspirates and biopsies were always morphologically normal, but one patient (patient 9) had minimal infiltration, demonstrated by positivity on molecular investigations.
In contrast, the two extra-abdominal tumors, located in the paratesticular area and in the superficial paravertebral muscles, were smaller than 5 cm and limited to the region of origin, with no evidence of distant spread. The EWS-WT1 transcript was detected in seven of eight tumors tested.
Treatment
After diagnostic surgery, initial chemotherapy consisted of the CEVAIE regimen in four patients and IVADo in nine (Table 1) . Tumor response to initial chemotherapy was evaluable in 10 patients, and seven responses (1 CR, 1 PR and 5 minor PR) were documented. SICT was considered inappropriate for the two patients with extra-abdominal localized disease and they continued with additional six cycles of standard chemotherapy. The same approach was adopted for the mentally retarded patient because of her poor general condition. Finally, one patient with SD after initial chemotherapy underwent surgery but the tumor progressed within a few weeks and the child continued to be on palliative therapy.
Overall, the SICT phase was administered to 10 patients and a further tumor volume reduction was apparent in 5 ( Table 1 ). The median time from the mobilizing cycles to 
Sequential high-dose chemotherapy for DSRCT G Bisogno et al the administration of the third HD cycle was 11.3 weeks (range 9-15.3). Surgery was performed in 12 patients (4 at diagnosis and 8 after SICT) and was complete in 2 children. Macroscopic tumor resection was possible in seven patients, whereas residuals were left in two. In one more case, no tumor lesions were found at surgery performed after SICT. Tumor resection was followed by radiotherapy in seven children. Radiotherapy was delivered to the primary tumor site in three cases. Whole abdominopelvic irradiation was used for six children with evidence of peritoneal implants. In one more child, radiotherapy was delivered to the primary tumor after surgery was deemed unfeasible due to the tumor extension. Irradiation was withheld in six patients for various reasons (Table 1) , that is, one patient with paratesticular DSRCT was in CR after initial surgery (patient 6), tumor progressed in one (patient 11), irradiation was unfeasible due to tumor extent in two (patients 2 and 4), at the center's discretion in one (patient 10) or due to poor general condition in one patient (patient 8).
Toxicity
Myelosuppression was the most notable side effect of the SICT, accompanied by fever in three patients and an episode of pneumonia in one. Apart from one child who suffered from a severe mucositis, no grade IV organ dysfunctions were reported. Two patients needed parenteral nutrition during whole abdominopelvic irradiation.
Outcome
Treatment failure became evident either during the treatment (two cases) or soon after it ended, with only one 'late relapse' 36 months after diagnosis. Overall, 12 patients achieved a clinical CR, but disease undetectable by imaging was suspected in most of them based on the results of surgery because microscopic residuals were left or small peritoneal nodules were noted. The reasons for treatment failure after CR were equally distributed, with three patients each suffering from local, distant or local and distant recurrences.
Concerning the seven children given aggressive local treatment including surgery and radiotherapy, two are alive in first CR whereas three had a local and two had a distant relapse. One more child with a paratesticular DSRCT is in first CR after complete tumor resection with no irradiation.
Another child is alive with evidence of disease 21 months after diagnosis, and one was lost to follow-up soon after multiple liver metastases became evident. With a median follow-up of 27 months for survivors, the 3-year OS and EFS for the whole group were 38.9 and 15.5%, respectively (Figure 1 ).
Discussion
The prognosis for patients with DSRCT has not improved substantially since it was first recognized by Gerald and Rosai in 1989. 4 The rarity of this tumor has so far precluded the development of dedicated protocols and most published series are retrospective reviews of single-center experiences, where patients have rarely been treated homogeneously. 5, 6, 11, 12 We report here on a multicenter study in which patients were treated prospectively according to an established protocol.
Most reports describe an initial response to intensive chemotherapy but, as in our experience, tumor relapse or progression occurred early, during or soon after the treatment.
The best results reported to date were obtained by Kushner et al.
2 at the Memorial Sloan-Kettering Cancer Center (MSKCC) using the P6 protocol, which involves seven courses of chemotherapy (including CY, doxorubicin and vincristine in courses 1, 2, 3 and 6, and ifosfamide and etoposide in courses 4, 5 and 7), and aggressive surgery and radiotherapy to high-risk sites. In their series, 5 of 10 previously untreated patients were reportedly alive in CR. Unfortunately, these promising results were not confirmed after a longer follow-up. A recent update on the MSKCC experience reported on 66 patients: the OS rate dropped from 44% at 3 years to 15% at 5 years. 13 Strategies to improve the outcome of DSRCT patients have included using a single HDCT cycle followed by PBSC rescue to consolidate the results obtained after several courses of chemotherapy and definitive local therapy. 6, 8, 11, 13, 14 Encouraging results were published by Fraser et al.,
8 who included four patients with DSRCT in a series of high-risk pediatric solid tumors. HDCT included BU, melphalan and thiotepa. As only one patient relapsed after a median follow-up of 3.2 years, the authors support the inclusion of alkylating-based high-dose regimens in the treatment of DSRCT. This opinion is shared by other authors who obtained positive results in limited series of patients. 12, 14 Recent experiences have used HDCT earlier. In particular, Bertuzzi et al.
7 described 10 adult patients with DSRCT, but only 5 of them achieved a PR after the initial four cycles of chemotherapy and proceeded to a single HDCT cycle with melphalan plus mitoxantrone or thiotepa, followed by PBSC reinfusion; no long-term survivors were reported and the median survival was 14 months (range 7-25).
In our initial experience, different regimens of intensive chemotherapy produced unsatisfactory results. 3 We then Sequential high-dose chemotherapy for DSRCT G Bisogno et al decided to enroll DSRCT patients in the RMS4.99 protocol, which was primarily designed for metastatic soft tissue sarcoma. This protocol was built on the experience of the MMT4 European protocol, where HDCT with melphalan was used to consolidate the CR achieved with intensive chemotherapy. 9 Despite an optimal initial response, the final results were unsatisfactory. The possible early onset of drug resistance and the ineffectiveness of a single HDCT for eradicating minimal residual disease have been suggested as possible explanations for these results.
To overcome these problems, and differently from previously published experiences, initial chemotherapy was immediately followed in the RMS4.99 study by multiple cycles of intensified chemotherapy with PBSC rescue. Melphalan, etoposide and thiotepa were used in this phase, as they are well-known agents that have already been tested in high-dose treatments against a variety of sarcomas, including DSRCT. [7] [8] [9] Doses were kept lower than the maximum tolerated to enable a short interval between cycles and avoid delaying local treatment measures excessively. The acute toxicity of this strategy was readily manageable and tumor response improved after SICT. Unfortunately, this did not lead to better tumor control, because the presence of metastatic lesions and/or invasive primary tumors prevented complete tumor resection in most patients. Adopting an aggressive strategy (including macroscopic tumor resection and irradiation of the primary tumor along with whole abdominopelvic irradiation in cases of peritoneal involvement) may have been of benefit in selected patients, as shown in two of our three disease-free patients. Radiotherapy probably improved local control, as only four out of eight irradiated patients relapsed in the irradiated field (but two of them had a metastatic relapse).
The good outcome in the patient with paratesticular tumor is consistent with previous findings indicating that non-metastatic DSRCT arising in this region may have a better prognosis. 15 The early occurrence of treatment failures showed that the SICT strategy was unable to prevent drug resistance and improve the prognosis for patients with DSRCT. Different approaches should consequently be attempted for this highly aggressive tumor.
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